Furthermore, the Rb1R654W/+ mutation, which corresponds to the RbR661W mutation identified from low penetrance Rbs, reduced the ability to bind E2F and promoted pituitary tumor development similar to the Rb+/− mutation 12, 13, 14. Here, RB1 is linked to pituitary tumor.